BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
BillionToOne announced the publication of a peer-reviewed study in The Journal of Liquid Biopsy demonstrating that its Northstar Response assay is a stronger predictor of survival than standard-of-care imaging for immunotherapy patients. Data from 142 patients across 12 solid tumor types showed molecular progression was the dominant independent predictor of survival with a hazard ratio of 5.3, detecting progression a median of 62 days before imaging.
Key figures
- Tumor types
- 12
- Patients enrolled
- 142
- Lead time median days
- 62
- Molecular rebound rate
- 1 in 4
- Hazard ratio molecular progression
- 5.3
- Hazard ratio combined progression landmark
- 13.8
- Hazard ratio combined progression longitudinal
- 19.7
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.